The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
Objective: Immune checkpoint inhibitors have revolutionized cancer therapy for multiple types of solid tumors, but as expected, a large percentage of patients do not show durable responses. Biomarkers that can predict clinical responses to immunotherapies at diagnosis are therefore urgently needed....
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
China Anti-Cancer Association
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9ca4f5ce4c1c4a9087e886fc3f620407 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9ca4f5ce4c1c4a9087e886fc3f620407 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9ca4f5ce4c1c4a9087e886fc3f6204072021-11-30T11:27:44ZThe commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms2095-394110.20892/j.issn.2095-3941.2020.0450https://doaj.org/article/9ca4f5ce4c1c4a9087e886fc3f6204072021-11-01T00:00:00Zhttp://www.cancerbiomed.org/index.php/cocr/article/view/1846https://doaj.org/toc/2095-3941Objective: Immune checkpoint inhibitors have revolutionized cancer therapy for multiple types of solid tumors, but as expected, a large percentage of patients do not show durable responses. Biomarkers that can predict clinical responses to immunotherapies at diagnosis are therefore urgently needed. Herein, we determined the associations between baseline gut commensal microbes and the clinical treatment efficiencies of patients with thoracic neoplasms during anti-programmed death protein 1 (PD-1) therapy. Methods: Forty-two patients with advanced thoracic carcinoma who received anti-PD-1 treatment were enrolled in the study. Baseline and time-serial stool samples were analyzed using 16S ribosomal RNA gene sequencing. Tumor responses, patient progression-free survival, and overall survival were used to measure clinical outcomes. Results: The diversities of the baseline gut microbiota were similar between responders (n = 23) and nonresponders (n = 19). The relative abundances of the Akkermansiaceae, Enterococcaceae, Enterobacteriaceae, Carnobacteriaceae and Clostridiales Family XI bacterial families were significantly higher in the responder group. These 5 bacterial families acted as a commensal consortium and better stratified patients according to clinical responses (P = 0.014). Patients with a higher abundance of commensal microbes had prolonged PFS (P = 0.00016). Using multivariable analysis, the abundance of the commensal consortium was identified as an independent predictor of anti-PD-1 immunotherapy in thoracic neoplasms (hazard ratio: 0.17; 95% confidence interval: 0.05–0.55; P = 0.003). Conclusions: Baseline gut microbiota may have a critical impact on anti-PD-1 treatment in thoracic neoplasms. The abundance of gut commensal microbes at diagnosis might be useful for the early prediction of anti-PD-1 immunotherapy responses.Huihui YinLu YangGongxin PengKe YangYuling MiXingsheng HuXuezhi HaoYuchen JiaoXiaobing WangYan WangChina Anti-Cancer Associationarticlegut microbiotacommensal microbesanti-pd-1 immunotherapythoracic neoplasmsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Biology & Medicine, Vol 18, Iss 4, Pp 1040-1052 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
gut microbiota commensal microbes anti-pd-1 immunotherapy thoracic neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
gut microbiota commensal microbes anti-pd-1 immunotherapy thoracic neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Huihui Yin Lu Yang Gongxin Peng Ke Yang Yuling Mi Xingsheng Hu Xuezhi Hao Yuchen Jiao Xiaobing Wang Yan Wang The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| description |
Objective: Immune checkpoint inhibitors have revolutionized cancer therapy for multiple types of solid tumors, but as expected, a large percentage of patients do not show durable responses. Biomarkers that can predict clinical responses to immunotherapies at diagnosis are therefore urgently needed. Herein, we determined the associations between baseline gut commensal microbes and the clinical treatment efficiencies of patients with thoracic neoplasms during anti-programmed death protein 1 (PD-1) therapy. Methods: Forty-two patients with advanced thoracic carcinoma who received anti-PD-1 treatment were enrolled in the study. Baseline and time-serial stool samples were analyzed using 16S ribosomal RNA gene sequencing. Tumor responses, patient progression-free survival, and overall survival were used to measure clinical outcomes. Results: The diversities of the baseline gut microbiota were similar between responders (n = 23) and nonresponders (n = 19). The relative abundances of the Akkermansiaceae, Enterococcaceae, Enterobacteriaceae, Carnobacteriaceae and Clostridiales Family XI bacterial families were significantly higher in the responder group. These 5 bacterial families acted as a commensal consortium and better stratified patients according to clinical responses (P = 0.014). Patients with a higher abundance of commensal microbes had prolonged PFS (P = 0.00016). Using multivariable analysis, the abundance of the commensal consortium was identified as an independent predictor of anti-PD-1 immunotherapy in thoracic neoplasms (hazard ratio: 0.17; 95% confidence interval: 0.05–0.55; P = 0.003). Conclusions: Baseline gut microbiota may have a critical impact on anti-PD-1 treatment in thoracic neoplasms. The abundance of gut commensal microbes at diagnosis might be useful for the early prediction of anti-PD-1 immunotherapy responses. |
| format |
article |
| author |
Huihui Yin Lu Yang Gongxin Peng Ke Yang Yuling Mi Xingsheng Hu Xuezhi Hao Yuchen Jiao Xiaobing Wang Yan Wang |
| author_facet |
Huihui Yin Lu Yang Gongxin Peng Ke Yang Yuling Mi Xingsheng Hu Xuezhi Hao Yuchen Jiao Xiaobing Wang Yan Wang |
| author_sort |
Huihui Yin |
| title |
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| title_short |
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| title_full |
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| title_fullStr |
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| title_full_unstemmed |
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms |
| title_sort |
commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (pd-1) therapy in thoracic neoplasms |
| publisher |
China Anti-Cancer Association |
| publishDate |
2021 |
| url |
https://doaj.org/article/9ca4f5ce4c1c4a9087e886fc3f620407 |
| work_keys_str_mv |
AT huihuiyin thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT luyang thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT gongxinpeng thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT keyang thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yulingmi thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xingshenghu thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xuezhihao thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yuchenjiao thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xiaobingwang thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yanwang thecommensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT huihuiyin commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT luyang commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT gongxinpeng commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT keyang commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yulingmi commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xingshenghu commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xuezhihao commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yuchenjiao commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT xiaobingwang commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms AT yanwang commensalconsortiumofthegutmicrobiomeisassociatedwithfavorableresponsestoantiprogrammeddeathprotein1pd1therapyinthoracicneoplasms |
| _version_ |
1718406639264989184 |